A MedTech Series A is not a SaaS Series A with a clinical slide bolted on. Product-market fit is the entry ticket, not the thesis. What a specialist MedTech investor actually underwrites at Series A is a concrete regulatory milestone inside reach, a credible clinical evidence plan under MDR Article 61, a post-market surveillance system that can survive ongoing compliance under Article 83, and an honest path to first real revenue that accounts for reimbursement. Founders who walk into a Series A meeting with growth charts and vague regulatory language lose the round in the first twenty minutes. Founders who can put the regulatory milestone, the clinical plan, and the revenue path on three clean slides, and defend them, close.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • A MedTech Series A is paced by regulatory milestones, not by MRR. The round is priced against how close the company is to CE mark and how defensible the clinical evidence strategy is.
  • Product-market fit in MedTech looks different from SaaS PMF. It is clinical pull, paid pilot commitments, and payer signal — not a usage curve.
  • A credible clinical evidence plan under MDR Article 61 is the single highest-leverage artefact in the data room. A vague plan kills the round silently.
  • Revenue traction at Series A in MedTech is rarely product revenue — it is letters of intent, paid pilots, and concrete reimbursement movement in at least one market.
  • Valuation at MedTech Series A is anchored to the regulatory milestone the round will clear, not to a SaaS comparable at the same headcount.

The Series A that died on the clinical slide

A founder Felix worked with had what looked, on paper, like a clean Series A story. Twelve paying pilot customers. A real product in real hospitals. A team that knew the domain. The deck opened with a growth chart that would have closed a SaaS round the same week.

The meeting with the lead investor went well until slide eleven. The clinical evidence slide. It said, essentially, that the company planned to use literature-based evaluation, that a small investigator-initiated study was under discussion with a clinical partner, and that the pivotal data would be "generated as part of the rollout." The investor — a specialist fund, someone who had funded three CE-marked devices already — stopped the meeting on that slide. Asked three questions. Got three soft answers. Thanked the team for their time.

The product was good. The pilot traction was real. The team was strong. None of that mattered, because the clinical evidence plan would not survive the investor's clinical diligence, and the investor knew it inside ninety seconds. The company spent another five months rebuilding the clinical strategy before any specialist fund would take a second meeting. The round closed eventually, at a materially lower valuation, with a clinical milestone tranche attached to the first tranche of capital.

That is what a MedTech Series A actually looks like. PMF gets you into the room. The regulatory milestone, the clinical plan, and the revenue path decide whether you leave with a term sheet.

What a MedTech Series A really is

In a SaaS company, Series A is the round where the investor bets on growth. Usage is proven, retention is proven, the playbook is clear enough to scale, and the round funds go-to-market. The metrics are well-known and the diligence is largely financial and commercial.

In a MedTech company, Series A is the round where the investor bets on the regulatory step-up. The central question is not "can this team grow faster with more capital," it is "can this team clear the next regulatory milestone cleanly and start generating real revenue afterwards." The round funds the run at CE mark, the final pieces of clinical evidence, the completion of the technical file under Annex II, and the commercial motion that begins once the device can legally be sold at scale.

This changes the entire shape of the pitch. A SaaS Series A deck leads with growth. A MedTech Series A deck leads with the regulatory milestone the round will clear, the clinical plan that supports it, and the revenue picture on the other side. Everything else — team, market, product — is support. The venture capital landscape shapes the specific terms you will see, but the underlying thesis is the same across every serious European specialist fund in 2026: fund the milestone, not the months.

PMF still matters. A founder who shows up without demonstrated clinical pull, named champions, and concrete customer commitment will not clear Series A either. But PMF alone does not close a MedTech round. PMF gets you into the conversation. What happens next depends on whether the regulatory and clinical story can survive specialist diligence.

The regulatory milestone the round needs to clear

Every MedTech Series A is priced against a specific regulatory milestone. The healthiest framing is that the round funds the company from its current regulatory state to the next defensible step-up, with enough buffer to absorb the delay that will happen. In practice, the Series A milestone is almost always one of the following:

  • Technical file substantially complete and submitted to the Notified Body.
  • Notified Body review underway, with responses to findings being addressed.
  • CE mark within clear reach on an honest timeline.
  • CE mark in hand and first commercial launch underway in a defined market.

A round that funds anything less ambitious than "meaningful movement toward CE mark" is not really a Series A — it is a larger seed. A round that funds more than that is a growth round, not a Series A. The language matters because it shapes the investor's expectations and the valuation reference class the deal will be compared against.

The mistake founders make is framing the round around headcount or runway: "we need 18 months and six hires." Specialist investors translate that back into regulatory progress immediately, and the translation is usually unflattering. The honest frame is the opposite — start with the regulatory milestone the round will clear, derive the team and activities required to clear it, then size the round against that work with an honest buffer. Felix's rule applies directly: estimate your real investment and time requirement honestly, then double it. A round sized to the doubled number survives reality. A round sized to the optimistic number triggers a bridge.

The Subtract to Ship framework cuts through this directly. Every line of spend in the round should trace to progress against the milestone. Headcount that does not buy milestone progress is dilution without valuation support. The round is not there to build a beautiful organisation. It is there to clear one specific regulatory gate.

The clinical evidence plan investors actually want

This is where most MedTech Series A rounds succeed or fail. The clinical evidence plan under MDR Article 61 is the load-bearing document in the entire round. A specialist fund will hire a clinical advisor to review it, and that advisor will read it with the same discipline a Notified Body reviewer would apply. Vague clinical strategies do not survive this.

A credible clinical evidence plan at Series A contains, at minimum:

  • A clinical evaluation strategy. Whether the evidence base is literature-based, equivalence-based, a new clinical investigation, or a combination — with the rationale for each choice tied to the device class and the intended purpose.
  • A clinical evaluation plan that follows Annex XIV. Not a PowerPoint paragraph, a real document that the Notified Body will see.
  • An honest read on whether a pre-market clinical investigation is required. For implantables and most Class III devices this is the default, with the narrow exemptions in MDCG 2023-7 well understood.
  • A budgeted, timed path to the pivotal evidence. Investigator-initiated data can be part of the story, but it cannot be the whole story unless the design supports regulatory use and the agreement with the site is tight.
  • A post-market clinical follow-up plan under Article 83. Clinical evidence generation does not stop at CE mark — the PMCF plan is part of the Series A story because it shapes the ongoing cost base.
  • A clear picture of who owns this work inside the company. If the founders cannot name the person responsible, the investor will assume there is no plan.

"We will figure out the clinical part later" is the single phrase that kills the most MedTech Series A rounds. Later is expensive. Every month spent figuring out the clinical strategy during the round is a month the company is burning runway without generating evidence, and specialist investors have watched this pattern drain companies they funded at seed.

The honest discipline is to start the clinical plan early, pressure-test it against a real clinical advisor before the round opens, and walk into Series A with a plan that has already survived at least one skeptical read. The cost of this is a few weeks of advisor time. The upside is a round that survives diligence.

Revenue traction in the MedTech context

"Traction" is the most dangerous word in a MedTech Series A pitch because it means something different here than it does in SaaS. A medical device above basic Class I cannot legally generate revenue until it has a CE mark, and CE mark is typically still ahead of the Series A. So the traction conversation is not about MRR. It is about evidence that the device will generate revenue once it legally can.

Specialist investors in 2026 want to see some combination of:

  • Paid pilots under narrow, compliant scope. A pilot in a hospital under a clear scope that fits within legal pathways — sometimes custom-made, sometimes clinical investigation, sometimes compassionate use — that both generates clinical data and demonstrates willingness to pay.
  • Letters of intent from clinical champions and buyers. Not vanity LOIs, but specific documents that name volumes, pricing, and trigger conditions. The specialist fund will follow up with at least one signatory.
  • Concrete reimbursement movement in at least one market. An engaged payer conversation, a DiGA application in Germany, a NICE discussion in the UK, a CPT code strategy in the US — something real, with dates.
  • KOL advocacy that shows up in writing. Published commentary, guideline participation, or co-investigator commitments from named clinical experts.
  • A commercial plan that does not assume a global launch on day one. Specialist investors prefer a sharp, narrow initial geography with a defensible reimbursement story over a slide that claims "the EU market."

What does not count as traction: hospital interest without any paperwork, "we are in talks with" statements, unpaid pilots that generate no data, and market-size slides derived from consulting reports. These are the signals of a team that has not yet done the work of turning PMF into a fundable commercial motion.

The honest Series A story on revenue is usually: here is the small set of early customers who will adopt on day one of CE mark, here are the pilot results that prove they will, here is the reimbursement work that makes adoption economically sustainable for them, and here is the budget to support the first year of commercial motion until the PMS data and the reimbursement wins compound. That story closes rounds.

How to frame valuation

Valuation at MedTech Series A is where founder expectations and investor math most often collide. A founder who has watched SaaS companies at similar headcount raise at large multiples naturally expects similar numbers. The specialist MedTech investor will not offer them, and the reason is structural.

The practical frame is to anchor the valuation to the regulatory milestone the round will clear. A Series A that funds a clean run at CE mark is priced against what that milestone is worth. A Series A that funds the first year of commercial launch after CE mark is priced higher, because the regulatory risk is smaller and the revenue horizon is closer. A Series A where the regulatory pathway is still genuinely uncertain is priced lower, because the investor is taking real technical risk alongside the execution risk.

Benchmark against European MedTech comparables at the same regulatory stage, not against SaaS comparables at the same headcount. A founder who inflates the valuation at Series A makes the Series B harder to raise, because the step-up requires evidence the company may not be able to deliver inside the round's timeline. We have watched this pattern repeatedly: a proud Series A at an inflated mark becomes a painful down round or a bridge at Series B, and the cap table damage is worse than accepting a lower but honest A in the first place.

One caveat worth stating plainly: the headline valuation is not the only term that matters. A higher mark with aggressive liquidation preferences, milestone tranching tied to subjective investor discretion, or a long exclusivity clause is almost always worse than a lower mark with clean terms. We cover the specific traps in venture capital for MedTech in Europe 2026. At Series A the stakes on these clauses rise sharply, because the round is larger and the preference stack lasts longer.

Common Series A mistakes

Five patterns that repeat in MedTech Series A rounds that fail or close on bad terms.

Treating Series A as a scaling round, not a milestone round. The founder pitches growth and hiring plans when the investor wants to hear about the regulatory step-up. The mismatch ends the meeting silently.

A clinical evidence plan that falls apart under diligence. The strategy reads well on the slide but cannot survive a specialist clinical advisor's read. By the time the founder realises this, the round is cold.

Confusing pilots with revenue. The deck claims "customers" and "traction" when the underlying documents are unpaid pilots with no clinical data and no purchase commitment. Specialist investors pull the paperwork in diligence.

Ignoring reimbursement until after CE mark. The investor asks about the reimbursement pathway and the founder says "we will deal with that after launch." In 2026, that answer ends the round with specialist funds, because they have watched too many CE-marked devices fail on payer coverage.

The exclusivity trap, again. The founder signs long exclusivity with the lead investor, the process slows, the terms soften at the last minute, and the company runs out of room to negotiate because it could not talk to anyone else. We covered this pattern at pre-seed and seed stage; it compounds at Series A because the round is bigger and the runway stakes are larger.

The Subtract to Ship angle

Applied to a MedTech Series A, Subtract to Ship says: strip every piece of the round that does not buy regulatory or commercial milestone progress, and keep the pieces that do. The vanity hires, the second product line, the global launch theatre, the conference budget — if they do not move the company closer to CE mark, first revenue, or first reimbursement win, they dilute without adding valuation support.

The load-bearing slides are the regulatory milestone slide, the clinical evidence slide, and the revenue path slide. Everything else is support. Most founders reverse this ordering and lose specialist investors in the first ten minutes. Reverse it back. Put the load-bearing slides near the front, defend them cold without hedging, and let the rest of the deck do its supporting job.

Tibor's framing applies directly: more money thrown at a vague regulatory plan is still a vague regulatory plan. The round only works if the underlying plan is real.

Reality Check — Where do you stand?

  1. Can you name the specific regulatory milestone this Series A will clear, in one sentence, without hedging?
  2. Is your clinical evaluation plan under Article 61 written as a real document, or only as slide bullets?
  3. Has your clinical plan been pressure-tested by a specialist clinical advisor outside your team, and did it survive that read?
  4. Do you have a concrete reimbursement pathway for at least one initial market, with names, dates, and evidence?
  5. Are your "traction" claims supported by paperwork a specialist investor can pull in diligence — LOIs with volumes, paid pilots with data, signed champions?
  6. Is your target round size anchored to the milestone and the doubled honest cost estimate, or to a headcount wish list?
  7. Does your target valuation benchmark against European MedTech comparables at your regulatory stage, not SaaS comparables at your headcount?
  8. Have you read every clause in your draft term sheet — exclusivity, preferences, milestone tranching, board control — with counsel who has closed MedTech Series A rounds specifically?

Frequently Asked Questions

What is the main difference between a MedTech Series A and a SaaS Series A? A SaaS Series A funds growth against proven usage and retention. A MedTech Series A funds the clearance of a specific regulatory milestone — usually CE mark or the run at it — with clinical evidence and a defensible revenue path on the other side. The metrics, the diligence, and the valuation math are all different.

Is product-market fit enough to raise a MedTech Series A? No. PMF is the entry ticket. Specialist investors need to see a regulatory milestone the round will clear, a clinical evidence plan under MDR Article 61 that survives diligence, and a concrete path to first revenue including reimbursement. A strong PMF story with a weak regulatory or clinical story will not close.

Do MedTech Series A investors expect real revenue before the round? Not usually product revenue, because most devices cannot legally sell until CE mark is in hand. Investors expect evidence that revenue will materialise after CE mark — paid pilots with data, letters of intent with volumes and pricing, reimbursement movement in at least one market, and a commercial plan that does not assume a global launch on day one.

What valuation should a European MedTech Series A target? Anchor the valuation to the regulatory milestone the round will clear, not to a SaaS comparable at the same headcount. A round funding a clean run at CE mark is priced against that step-up. A round funding the first year of commercial launch post-CE is priced higher. Inflating the mark at Series A makes the Series B materially harder.

How long does a MedTech Series A process take? Eight to sixteen weeks from first meeting to signed term sheet is typical for specialist funds, with additional time to closing. Rushing the process is a warning sign on both sides. Founders with short runway lose negotiating leverage and sign worse terms.

What is the single most important artefact in a MedTech Series A data room? The clinical evaluation plan under MDR Article 61 and its supporting clinical evidence strategy. A specialist fund will hire a clinical advisor to review it, and that review decides the round more often than any other single document.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations), Article 61 (clinical evaluation), Article 83 (post-market surveillance system). Official Journal L 117, 5.5.2017.
  2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.

This post is part of the Funding, Business Models and Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The Series A is the round where the shape of the company becomes visible to the market. Get the regulatory milestone, the clinical plan, and the revenue path right, defend them cold, and the round that follows will be a round you are still happy with three years from now.